<DOC>
	<DOCNO>NCT01486524</DOCNO>
	<brief_summary>The overall purpose study determine whether either Improved Response Polymorphisms ( IRPs ) individually predict differential DrotAA treatment effect patient severe sepsis high risk death . This international , multicenter , `` prospective-retrospective '' , nonrandomized , control , outcome-blinded , genotype-blinded , matched-patients study . No prospective enrollment treatment patient occur protocol . Retrospectively collected clinical data DNA sample analyze exist cohort patient severe sepsis previously treat DrotAA ( treatment group ) ( control group ) part standard care ICU .</brief_summary>
	<brief_title>Pharmacogenomic Biomarker Study Recombinant Human Activated Protein C Treatment Severe Sepsis</brief_title>
	<detailed_description>This multicenter , `` prospective-retrospective '' , control , matched-patients study . Retrospective phenotypic data DNA sample obtain patient registry clinical trial study hypothesis related DrotAA treatment . The prospective aspect study statistical test prespecified hypothesis regard IRP genotype predictive biomarker differential DrotAA treatment effect . To control difference standard care different country medical center , selection match control patient perform within cohort . Control patient select match DrotAA-treated patient use algorithm match baseline demographic disease characteristic may influence decision give DrotAA may impact survival . A propensity score ( likelihood receive DrotAA treatment ) derive use match variable common cohort . The number match control patient treat patient variable , maximum 3 . The selection control patient via match algorithm conduct independent clinical research organization ( CRO ) blind manner - specifically without knowledge survival outcome , outcome data , genotype . A two-phase transfer data center implement ensure selection match control patient implement blinded manner . The first step involve transfer baseline data variable need conduct match . Once control patient identify cohort , outcomes data transfer CRO second phase data transfer . Centralized genotyping use validated Taqman®-based analytical method conduct DNA sample match patient . The genotyping laboratory blind treatment outcome . The total number patient available cohort &gt; 23,000 , approximately 800 receive DrotAA part standard ICU-based care . After apply eligibility criterion patient select match control patient , expect final analysis include approximately 3000 patient .</detailed_description>
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Toxemia</mesh_term>
	<mesh_term>Shock , Septic</mesh_term>
	<mesh_term>Drotrecogin alfa activate</mesh_term>
	<mesh_term>Protein C</mesh_term>
	<criteria>Inclusion Criteria INDICATED population : 1 . Age ≥ 18 year 2 . Severe sepsis ( must meet , b , c ) Suspected proven infection Systemic Inflammatory Response Syndrome ( SIRS ) ( must meet 2 4 criterion ) Temperature &lt; 36°C &gt; 38°C Heart rate &gt; 90 beats/minute Respiratory rate &gt; 20 breaths/minute PaC02 &lt; 32 mm Hg ) mechanical ventilation White blood cell count &lt; 4,000/mm3 &gt; 12,000/mm3 At least one organ dysfunction due sepsis base definition clinically significant organ dysfunction Cardiovascular dysfunction [ must meet one ( 1 ) , ( 2 ) , ( 3 ) ] : Systolic blood pressure ≤ 90 mmHg pH ≤ 7.3 Mean arterial pressure ≤ 70 mmHg pH ≤ 7.3 Reported use vasopressor alone sufficient evidence shock Pulmonary dysfunction : PaO2/FiO2 ≤ 300 mmHg Central Nervous System dysfunction : Glasgow Coma Scale ≤ 12 Coagulation dysfunction : platelet ≤ 80,000/mm3 Renal dysfunction : creatinine ≥ 2.0 mg/dL Hepatic dysfunction : bilirubin ≥ 2.0 mg/dL 3 . High risk death ( one , b , c ) APACHE II ≥ 25 SAPS II ≥ 54 Multiple organ dysfunction two clinically significant organ dysfunction ( define ) , occur within 2 day 4 . Platelet count ≥ 30,000/mm3 5 . DrotAA status know 1 . Patients DNA 2 . Patients enrol local cohort 2 year Xigris [ drotrecogin alfa activate ) ] commercially available A secondary analysis population severe sepsis define Inclusion Criteria 1 , 2 , 4 , 5 , Exclusion Criteria . This refer SEVSEP population .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>pharmacogenomic biomarker</keyword>
	<keyword>predictive marker</keyword>
	<keyword>prospective-retrospective</keyword>
	<keyword>propensity score</keyword>
	<keyword>matched-patients trial</keyword>
</DOC>